Clinical Trial Update: Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer [Phase 1]

View source ↗

Summary

A Phase 1 dose-finding study of cabozantinib (XL184) in Japanese subjects with advanced cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Exelixis | Conditions: Solid Tumors, Cancer | Phase 1 | Status: COMPLETED